Cite
Risk of Severe Sars-Cov-2 Infections in COVID-19 Vaccinated Individuals with Hematologic Malignancies (SAVE HEM): A Nationwide Cohort Study in the Netherlands
MLA
Hofsink, Quincy, et al. “Risk of Severe Sars-Cov-2 Infections in COVID-19 Vaccinated Individuals with Hematologic Malignancies (SAVE HEM): A Nationwide Cohort Study in the Netherlands.” Blood, vol. 142, no. 1, Number 1 Supplement 1, Nov. 2023, p. 546. EBSCOhost, https://doi.org/10.1182/blood-2023-188561.
APA
Hofsink, Q., Haggenburg, S., Lissenberg-Witte, B. I., Goorhuis, A., Hazenberg, M. D., Rutten, C. E., Zweegman, S., Kemmeren, J., de Keizer, N. F., Huijgens, P. C., Dinmohamed, A. G., van den Hof, S., de Gier, B., Knol, M., Hahné, S., Heijmans, J., & Nijhof, I. S. (2023). Risk of Severe Sars-Cov-2 Infections in COVID-19 Vaccinated Individuals with Hematologic Malignancies (SAVE HEM): A Nationwide Cohort Study in the Netherlands. Blood, 142(1, Number 1 Supplement 1), 546. https://doi.org/10.1182/blood-2023-188561
Chicago
Hofsink, Quincy, Sabine Haggenburg, Birgit I. Lissenberg-Witte, Abraham Goorhuis, Mette D. Hazenberg, Caroline E. Rutten, Sonja Zweegman, et al. 2023. “Risk of Severe Sars-Cov-2 Infections in COVID-19 Vaccinated Individuals with Hematologic Malignancies (SAVE HEM): A Nationwide Cohort Study in the Netherlands.” Blood 142 (1, Number 1 Supplement 1): 546. doi:10.1182/blood-2023-188561.